;

Rexgenero Appoints Sadia L’Baouch as Chief Manufacturing Officer

07/12/2020

Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischemia (CLTI), today announces the appointment of Sadia L’Baouch as Chief Manufacturing Officer, effective 4 January 2021.

Sadia has more than 20 years’ experience in manufacturing operations, supply chain management and external supply. She has a successful track record in devising strategy and infrastructures for new products and managing multiple sites.

Sadia will join Rexgenero from Sangamo Therapeutics where, as Senior Director of Supply Chain and Manufacturing, she managed CMOs for delivery of early phase programmes using CAR-Tregs (chimeric antigen receptor regulator T cells). Prior to Sangamo Therapeutics, Sadia spent 17 years at GlaxoSmithKline in roles such as Operations and Supply Director, Director of Manufacturing and Supply, and Supply Chain Senior Director where she led on supply chain for the launch of the first ex-vivo gene therapy Strimvelis. She transitioned to Orchard Therapeutics in 2018 following its acquisition of the GSK Rare Diseases portfolio to act as Supply Chain Senior Director. There she continued to manage global supply chain operational aspects for autologous cell and gene therapy products for both clinical and commercial supplies.

Joe Dupere, CEO of Rexgenero, commented: “Sadia is a fantastic addition to our leadership team. Her in-depth knowledge and proven track record in manufacturing operations and supply across multiple cell and gene therapy programmes will be invaluable as we progress both our REX-001 clinical candidate for chronic limb-threatening ischemia toward commercialization and our in vivo CAR-T platform.”

Sadia L’Baouch, newly appointed Chief Manufacturing Officer of Rexgenero, commented: “I’m glad to be joining Rexgenero at such a pivotal time for the company, having followed the acquisition of the in vivo CAR-T technology with great interest. I look forward to working with Joe and the rest of the team to push forward our integrated cell and gene therapy platform and cell therapy assets.”

Sadia has an MSc in Chemical Engineering from the University of Compiégne, France, and an MBA in Business Administration from Warwick University, UK. She is an AIM Accredited Change Manager, and an IChemE Chartered Chemical Engineer.

innovative cell therapies
Contact us